ProQR Therapeutics NV (PRQR) EUR0.04

Sell:$2.00Buy:$2.12$0.02 (0.95%)

Prices delayed by at least 15 minutes
Sell:$2.00
Buy:$2.12
Change:$0.02 (0.95%)
Prices delayed by at least 15 minutes
Sell:$2.00
Buy:$2.12
Change:$0.02 (0.95%)
Prices delayed by at least 15 minutes

Company Information

About this company

ProQR Therapeutics N.V. is a biotechnology company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The Company operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).

Key people

Daniel Anton de Boer
Chief Executive Officer, Founder, Executive Director
Dennis Hom
Chief Financial Officer
Sheila Sponselee
Chief People and Operations Officer
Gerard Platenburg
Chief Scientific Officer, Executive Director
Rene K. Beukema
Chief Corporate Development Officer, General Counsel, Executive Director
Cristina Lopez
Chief Medical Officer
James Samuel Shannon
Independent Non-Executive Chairman of the Board
Theresa M. Heggie
Non-Executive Director
Dinko Valerio
Non-Executive Director
Begona Carreno
Non-Executive Independent Director
Bart Filius
Non-Executive Independent Director
Click to see more

Key facts

  • EPIC
    PRQR
  • Location
    Netherlands
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    NL0010872495
  • Market cap
    $221.37m
  • Employees
    166
  • Shares in issue
    107.71m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.